Mar 01, 2022 08:38 AM (GMT+8) · EqualOcean
On February 28, local time, the US market application (BLA) of legendary biology's cilta cel (R & D Code: lcar-b38m) was approved by FDA for the treatment of adult recurrent / refractory multiple myeloma (mm), becoming the first cell therapy product approved by FDA in China and the second car-t cell immunotherapy approved to target BCMA in the world.